-transparent.png){kind=logo}
The response of sustained supraventricular tachycardia to intravenous and oral flecainide acetate was investigated in 5 children, aged 5.5 to 11.5 years, who had tachycardias associated with Wolff-Parkinson-White syndrome. All children had failed to respond to at least 2 conventional agents. The effect of flecainide was studied using intracardiac techniques. Intravenous flecainide terminated tachycardia in all 5 patients. After drug infusion, slow, sustained tachycardia could be initiated in 1 patient. With oral treatment, slow, sustained tachycardia was started in 2 children and nonsustained in 2. One child had no inducible tachycardias. In 4 of 5 patients, long-term treatment has reduced the frequency of episodes and the drug is well tolerated. Thus, flecainide may be used to terminate and suppress junctional tachycardias in children who have failed to respond to conventional therapy.
D E Ward, and
S Jones, and
E A Shinebourne
August 1992,
The American journal of cardiology,
D E Ward, and
S Jones, and
E A Shinebourne
June 1985,
Clinical cardiology,
D E Ward, and
S Jones, and
E A Shinebourne
January 1983,
Archives des maladies du coeur et des vaisseaux,
D E Ward, and
S Jones, and
E A Shinebourne
February 1979,
Boletin de la Asociacion Medica de Puerto Rico,
D E Ward, and
S Jones, and
E A Shinebourne
November 1984,
Soins. Cardiologie,
D E Ward, and
S Jones, and
E A Shinebourne
April 1982,
La Nouvelle presse medicale,
D E Ward, and
S Jones, and
E A Shinebourne
April 1990,
Archives des maladies du coeur et des vaisseaux,
D E Ward, and
S Jones, and
E A Shinebourne
November 1991,
Pacing and clinical electrophysiology : PACE,
D E Ward, and
S Jones, and
E A Shinebourne
August 1986,
The American journal of cardiology,
D E Ward, and
S Jones, and
E A Shinebourne
March 1982,
Revista medica de Chile,
